Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
‘Patients treated with DES do not live longer’
A study presented in a Hot Line session yesterday suggested that a decoy protein can rapidly reverse potentially life-threatening bleeding effects associated with anticoagulants.
Interim results from the ongoing ANdexanet alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors (ANNEXA-4) study, published simultaneously in the New England Journal of Medicine, show the antidote andexanet alfa reduces anticoagulant activity within half an hour in nearly 90% of patients.
NOACs are considered safe but are associated with increased risk of major gastrointestinal bleeding. Andexanet alfa is the first agent designed to reverse effects of these newer oral anticoagulants which inhibit factor Xa enzyme. A modified recombinant derivative of factor Xa, andexanet alfa acts as a decoy receptor.
It has been shown to reduce anti-fXa activity in volunteers but, until now, there was no data for acutely bleeding patients. The interim results from the ANNEXA-4 study are based on 67 patients with a mean age of 77 years requiring urgent reversal of acute major bleeding. This was within 18 hours of receiving either a direct fXa inhibitor (such as apixaban, rivaroxaban or edoxaban) or an indirect one (enoxaparin).
The main site of bleeding was either gastrointestinal (49%) or intracranial (42%). The study was not randomised (for ethical reasons) and all patients received andexanet, first in an immediate IV bolus over 15 to 30 minutes and then followed by a two hour IV infusion. Dosing was based on exposure to fXa inhibitor.
Patients were assessed at baseline, at end-of-bolus, and at end of the two-hour infusion. Assessment also took place at four, eight and 12 hours, and safety follow-up visits occurred at three and 30 days post-infusion.
The primary outcomes were based on primary efficacy measurements and on safety measurements. The former included change in anti-fXa activity and clinical hemostatic efficacy through 12 hours using independent adjudication committee with pre-specified precise evaluation criteria. The latter covered overall safety; thrombotic events; antibodies to FX, FXa, andexanet; and 30-day all-cause mortality.
The interim results reported an 89% decrease in anti-fXa activity from baseline to end-of-bolus for those patients exposed to rivaroxaban, and a 93% reduction for those exposed to apixaban. Clinical haemostatic efficacy was rated as ‘excellent or good’ in 79% of patients at 12 hours.
Thrombotic events occurred in 18% of patients during 30 day follow-up. Study presenter Stuart Connolly from McMaster University in Canada.said this was not unexpected given the ‘highly compromised’ profile of patients and that anticoagulation was discontinued at the time of bleeding and not restarted.
‘The preliminary report of the ongoing ANNEXA-4 study shows us that andexanet rapidly reverses anti-factor Xa activity in acutely bleeding patients and this is associated with excellent or good haemostatis in most,’ Connolly.added.
Click here to read other scientific highlights in the full edition of the Congress news.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
About ESC Congress 2016
ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2016 takes place 27 to 31 August at the Fiera di Roma in Rome, Italy. The full scientific programme is here.
© 2017 European Society of Cardiology. All rights reserved